Form 4: Solen Therapeutics Executive Sells Shares to Cover Tax Obligations

A Soleno Therapeutics executive, Patricia C Hirano, sold shares to cover tax obligations related to vesting restricted stock units.

Summary

• Patricia C Hirano, a Senior Vice President at Soleno Therapeutics, sold a total of 3,030 shares of common stock across three transactions.
• The sales occurred on January 2, 2025, and January 3, 2025.
• The shares were sold at weighted average prices of $45.3656, $45.92 and $46.1764 respectively.
• These sales were made to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs).
• Following these transactions, Ms. Hirano directly owns 105,902 shares of Soleno Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing for insider transactions, which is neither positive nor negative. It reflects standard practice for executives managing their stock-based compensation.

Industry Context

This is a routine filing related to insider transactions and is common for executives who receive stock-based compensation. It does not indicate any specific trend or issue within the pharmaceutical industry.

Comparison to Industry Standards

• Executive stock sales to cover tax obligations are a common practice across all industries, including the pharmaceutical sector.
• These transactions are typically disclosed via SEC Form 4 filings, which are standard for publicly traded companies.
• The volume of shares sold is relatively small compared to the total outstanding shares of the company, and is not unusual for an executive's tax obligations.

Stakeholder Impact

• The stock sales are unlikely to have a significant impact on shareholders, as they are routine transactions for tax purposes.
• The sales do not indicate any change in the company's performance or outlook.

Key Dates

Keywords

insider trading, stock sale, restricted stock units, tax obligations, executive, Solen Therapeutics, SLNO